JANX008
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Trial Timeline
Apr 19, 2023 → Oct 1, 2027
NCT ID
NCT05783622About JANX008
JANX008 is a phase 1 stage product being developed by Janux Therapeutics for Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05783622. Target conditions include Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05783622 | Phase 1 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Cancer